These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26369347)

  • 1. HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment.
    Juusola JL; Brandeau ML
    Med Decis Making; 2016 Apr; 36(3):391-409. PubMed ID: 26369347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
    Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
    Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
    Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
    PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
    Zhang L; Phanuphak N; Henderson K; Nonenoy S; Srikaew S; Shattock AJ; Kerr CC; Omune B; van Griensven F; Osornprasop S; Oelrichs R; Ananworanich J; Wilson DP
    Lancet HIV; 2015 May; 2(5):e200-7. PubMed ID: 26423002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
    Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
    BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decision analytics model to optimize investment in interventions targeting the HIV preexposure prophylaxis cascade of care.
    Jenness SM; Knowlton G; Smith DK; Marcus JL; Anderson EJ; Siegler AJ; Jones J; Sullivan PS; Enns E
    AIDS; 2021 Jul; 35(9):1479-1489. PubMed ID: 33831910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
    van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease.
    Kazemian P; Costantini S; Neilan AM; Resch SC; Walensky RP; Weinstein MC; Freedberg KA
    J Biomed Inform; 2020 Jul; 107():103475. PubMed ID: 32526280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men.
    Ross EL; Cinti SK; Hutton DW
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal investment in a portfolio of HIV prevention programs.
    Zaric GS; Brandeau ML
    Med Decis Making; 2001; 21(5):391-408. PubMed ID: 11575489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
    Ginsberg GM; Chemtob D
    BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men.
    McKenney J; Chen A; Hoover KW; Kelly J; Dowdy D; Sharifi P; Sullivan PS; Rosenberg ES
    PLoS One; 2017; 12(6):e0178170. PubMed ID: 28570572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of a Statewide Pre-Exposure Prophylaxis Program for Gay, Bisexual, and Other Men Who Have Sex with Men.
    Goedel WC; Chan PA; King MRF; Prosperi MCF; Marshall BDL; Galárraga O
    R I Med J (2013); 2019 Nov; 102(9):36-39. PubMed ID: 31675786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
    Alistar SS; Grant PM; Bendavid E
    BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.